"Bear...Can we conclude that based on this data, ABL would compete with current medicine for Congestive Heart Failure? Or is this data only related to MACE prevention only?"

If I recall, DM mentioned that apabetalone had benefit twice as large as observed for a leading heart failure medication, Entresto. So this sounds like apabetalone competing with and potentially beating leading standard of care.

Congestive Heart Failure (CHF) in Total Population: In the total population, there was a 41% reduction for first hospitalization for CHF (95% CI; 0.38-0.94) p=0.03. Also 53% reduction for first and recurrent hospitalization for CHF. If stroke was replaced with first hospitalization for CHF in the 3-point MACE composite, there would have been a 24% reduction with p=0.02. DM mentioned that this is twice the effect of heart failure medication Entresto and that CHF market is twice that of the stroke market. An exploratory outcome composite of first hospitalization for CHF or cardiovascular death showed a 27% reduction (p=0.04). CHF partnering discussions ASAP, already initiated.